Defining interferon beta response status in multiple sclerosis patients

Annals of Neurology
R RudickElizabeth Fisher

Abstract

IFN-beta is effective in reducing relapses and magnetic resonance imaging (MRI) lesions in multiple sclerosis (MS). It is assumed that individual therapeutic responses vary, but methods to identify IFN-beta responsiveness have not been validated. Our objective was to evaluate methods to classify IFN-beta responder status using relapses and MRI lesions. Data was analyzed from 172 patients who were followed up in a placebo-controlled clinical trial of IFN-beta1a for 2 years. Patients were classified as responders or nonresponders using (1) the number of relapses during the 2-year trial; (2) the number of new T2 lesions after 2 years; and (3) the number of gadolinium-enhancing lesions at year 1 and year 2 on study. Outcomes included 2-year change in the Expanded Disability Status Scale, Multiple Sclerosis Functional Composite, and brain parenchymal fraction. We found that subgroups with high on-study relapse numbers had more disease progression, differences between responder subgroups were similar in the IFN-beta1a and placebo arms. In contrast, subgroups with high numbers of new MRI lesions had significantly more disease progression only in the IFN-beta1a arm. Baseline characteristics failed to account for differential outcome. N...Continue Reading

References

Dec 1, 1995·Brain : a Journal of Neurology·M FilippiD H Miller
Jan 1, 1995·Duodecim; lääketieteellinen aikakauskirja·M PaneliusJ Ruutiainen
Feb 24, 2001·Multiple Sclerosis : Clinical and Laboratory Research·E FisherN A Simonian
May 30, 2001·Lancet·G ComiUNKNOWN Early Treatment of Multiple Sclerosis Study Group
Jan 18, 2002·The New England Journal of Medicine·Peter A BrexDavid H Miller
Nov 26, 2002·Journal of Neuroimmunology·J KillesteinC H Polman

❮ Previous
Next ❯

Citations

Sep 10, 2005·Journal of Neurology·Valentina TomassiniCarlo Pozzilli
Mar 28, 2009·Journal of Neurology·Robert H GoertschesUwe K Zettl
Oct 4, 2008·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Marco Rovaris
Dec 25, 2012·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Corey A McGraw, Fred D Lublin
Oct 10, 2012·The Pharmacogenomics Journal·V Foti CuzzolaS Marino
Jun 22, 2007·The New England Journal of Medicine·Richard M Ransohoff
Mar 3, 2006·The New England Journal of Medicine·Richard A RudickUNKNOWN SENTINEL Investigators
Dec 27, 2005·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·M R Sandhya Rani, Richard M Ransohoff
Jun 3, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L F van der VoortJ Killestein
Jun 23, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·L ProsperiniC Pozzilli
Jul 21, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·N PutzkiV Limmroth
Nov 1, 2008·Therapeutic Advances in Neurological Disorders·Peter RieckmannJoel Oger
Aug 6, 2008·Journal of Leukocyte Biology·Laura PiccioAnne H Cross
Dec 24, 2008·Pharmacogenomics·Saskia VosslamberCornelis L Verweij
May 20, 2009·Pharmacogenomics·Koen VandenbroeckPablo Villoslada
Sep 6, 2011·Annual Review of Medicine·Daniel OntanedaJeffrey A Cohen
Aug 2, 2014·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Jerome J Graber, Suhayl Dhib-Jalbut
Jul 6, 2013·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Massimo FilippiNicola De Stefano
Apr 23, 2013·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Mark S FreedmanUNKNOWN Canadian Multiple Sclerosis Working Group
May 24, 2011·Radiology·Massimo Filippi, Maria A Rocca
Aug 29, 2014·Molecular Diagnosis & Therapy·Violaine K Harris, Saud A Sadiq
Mar 11, 2009·Expert Review of Neurotherapeutics·Carlo PozzilliLuca Prosperini
Apr 21, 2006·Expert Review of Neurotherapeutics·Francesca BagnatoVasiliki N Ikonomidou
Mar 15, 2006·Expert Review of Neurotherapeutics·Dean M Wingerchuk
Apr 5, 2015·Expert Opinion on Biological Therapy·Chiara ZeccaClaudio Gobbi
Aug 13, 2008·Expert Opinion on Biological Therapy·Bianca Weinstock-GuttmanRobert Zivadinov
Nov 14, 2008·Expert Opinion on Pharmacotherapy·Iván Martinez-ForeroPablo Villoslada
Aug 15, 2009·Current Medical Research and Opinion·Mark S FreedmanBianca Weinstock-Guttman
Nov 12, 2015·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Giselle Pentón-RolEduardo Pentón-Arias
Feb 20, 2016·Neurology. Neuroimmunology and Neuroinflammation·Harald HegenRobert C Axtell
Nov 28, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Pierre DuquetteRobyn Schecter
Apr 10, 2012·Pharmacology & Therapeutics·Peter M GeorgeJane A Mitchell
Jun 10, 2008·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Elke WiesemannAnja Windhagen
Apr 29, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M FilippiJ S Wolinsky
Jul 6, 2014·Journal of Neurology·Douglas L ArnoldKatherine T Dawson
Apr 22, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Anthony TraboulseeDavid K B Li

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.